Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Free Cash Flow (2016 - 2025)

Spyre Therapeutics' Free Cash Flow history spans 11 years, with the latest figure at -$44.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 19.84% year-over-year to -$44.6 million; the TTM value through Dec 2025 reached -$169.3 million, down 7.52%, while the annual FY2025 figure was -$169.3 million, 7.52% down from the prior year.
  • Free Cash Flow reached -$44.6 million in Q4 2025 per SYRE's latest filing, down from -$37.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.5 million in Q2 2021 to a low of -$62.2 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$27.9 million, with a median of -$27.4 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 113.59% in 2021, then tumbled 923.95% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$19.3 million in 2021, then grew by 5.85% to -$18.1 million in 2022, then plummeted by 71.09% to -$31.0 million in 2023, then dropped by 19.86% to -$37.2 million in 2024, then fell by 19.84% to -$44.6 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Free Cash Flow are -$44.6 million (Q4 2025), -$37.1 million (Q3 2025), and -$46.6 million (Q2 2025).